CO4980857A1 - Piridinas biciclicas, intermediarios de ellas, proceso para su preparacion y preparaciones farmaceuticas que contienen las mismas. - Google Patents

Piridinas biciclicas, intermediarios de ellas, proceso para su preparacion y preparaciones farmaceuticas que contienen las mismas.

Info

Publication number
CO4980857A1
CO4980857A1 CO98060325A CO98060325A CO4980857A1 CO 4980857 A1 CO4980857 A1 CO 4980857A1 CO 98060325 A CO98060325 A CO 98060325A CO 98060325 A CO98060325 A CO 98060325A CO 4980857 A1 CO4980857 A1 CO 4980857A1
Authority
CO
Colombia
Prior art keywords
alkyl
hydrogen
amino
heteroalkyl
heterocyclylalkyl
Prior art date
Application number
CO98060325A
Other languages
English (en)
Inventor
Cheng Soan
David Michael Goldstein
Martin Teresa Alejandra Trejo
Eric Brian Sjogren
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO4980857A1 publication Critical patent/CO4980857A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto seleccionado del grupo de compuestos representadospor la fórmula(I): en los que: R1 es heteroarilo; ------representa un enlace entre o bien B y CR1 o Q y CR1 de modo que: (i) cuando------ es entre Q y -CR1 -entonces: B es nitrógeno; R2 es arilo; y Q es -CR- donde: R es hidrógeno, alquilo, haloalquilo, cicloalquilo, R2 es arilo; y Q es -CR-donde:R es hidrógeno, alquilo, haloalquilo, cicloalquilo, cicloalquilalquilo, heteroalquilo, acilo, heterociclilo, heterociclilalquilo, heterociclilcarbonilo, nitro, ciano, amino, amino monosubstituido, amino disubstituido, acilamino, sulfonilamino, -OR5 (donde R5 es hidrógeno, alquilo, heteroalquilo, o heterociclilalquilo), -COOR7 (donde R7 es hidrógeno o alquilo) o -CONR´R" (donde R´y R" independientemente representan hidrógeno, alquilo o heteroalquilo); y (ii) cuando ------ es entre B y -CR1 -entonces: B es carbono; R2 es arilo o heteroarilo; y Q es -NR4 -, -O-, o -S-donde: R4 es hidrógeno, alquilo, alquenilo, alquinilo, haloalquilo, cicloalquilo, cicloalquilalquilo, heteroalquilo, acilo, aralquilo, heteroaralquilo, heterociclilo, heterociclilalquilo, heterociclilcarbonilo, -OR5 (donde R5 es hidrógeno, alquilo, heteroalquilo, o heterociclilalquilo), - 2 --SO2 R" (donde R" es alquilo, amino, amino monosubstituido o amino disubstituido), -CONR´R" (donde R´y R" independientemente representan hidrógeno, alquilo, o heteroalquilo), -(alquileno)-Z o -(alquileno)-CO-(alquileno) -Z donde: Z es ciano; -COOR7 donde R7 es hidrógeno o alquilo; -CONR8 R9 donde R8 es hidrógeno o alquilo, R9 es alcoxi o -(alquileno)-COOR7 , o R8 y R9 junto con el átomo de nitrógeno con el que están unidos forman un heterociclo; -C(=NR10 )(NR11 R12 )donde R10 , R11 y R12 independientemente representan hidrógeno o alquilo, o R10 y R11 juntos son -(CH2 )n -donde n es 2 ó 3 y R12 es hidrógeno o alquilo; o -COR13 donde R13 es alquilo, heteroalquilo, heterociclilalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo, y es un grupo representado por la fórmula (S), (T), (U), (V) o (W); donde: R6 es hidrógeno, alquilo, heteroalquilo, heterociclilalquilo, halo, ciano, nitro, amino, amino monosubstituido, amino disubstituido, -COOR14 , -(alquileno)-COOR14 (donde R14 es hidrógeno o alquilo), -CONR15 R16 (donde R15 y R16 independientemente representan hidrógeno o alquilo, o R15 y R16 junto con el átomo de nitrógeno con el que están unidos forman un heterociclo), -S(O)n R17 (donde n es un entero de O a 2 y R17 es alquilo, amino, amino monosubstituido o amino disubstituido), -OR18 (donde R18 es hidrógeno, alquilo, heteroalquilo o heterociclialquilo), -NRC(O)R" [donde R es hidrógeno, alquilo o hidroxialquilo y R" es hidrógeno, alquilo, cicloalquilo, o -(alquileno)-X donde X es hidroxi, alcoxi, amino, alquilamino, dialquilamino, heterociclilo o -S(O)n R´ (donde n es de 0 a 2 y R´ es alquilo)], -NRSO2 R" [donde R es hidrógeno o alquilo y R´´ es alquilo o -(alquileno)-X donde X es hidroxi, alcoxi, amino, alquilamino, dialquilamino o -S(O)n R´ (donde n es de 0 a 2 y R´ es alquilo)]; y R3 es hidrógeno, alquilo, alquenilo, alquinilo, haloalquilo, heteroalquilo, cicloalquilo, cicloalquilalaquilo, cicloalquiltio, aralquilo, heteroaralquilo, heterociclilo, heterociclilalquilo, halo, ciano, nitro, amino, amino monosubstituido, amino disubstituido, acilamino, sulfonilamino, -OR19 (donde R19 es hidrógeno, alquilo, heteroalquilo, o heterociclilalquilo), -COOR20 (donde R20 es hidrógeno o alquilo), -CONR21 R22 (donde R21 y R22 independientemente representa hidrógeno, alquilo o heteroalquilo, o R21 y R22 juntos con el átomo de nitrógeno con el que están unidos forman un heterociclo, -S(O)n R23 (donde n es un entero de 0 a 2 y R23 es alquilo, heteroalquilo, amino, amino monosustituido o amino disubstituido), -(alquileno)-Z" o -(alquileno)-CO-(alquileno)-Z" donde: Z" es ciano; -COOR24 donde R24 es hidrógeno o alquilo; -CONR25 R26 donde R25 R26 independientemente representan hidrógeno o alquilo, o R25 y R26 juntos con el átomo de nitrógeno con el que están unidos forman un heterociclo; -C(=NR27 ) (NR28 R29 ) donde R27 , R28 y R29 independientemente representan hidrógeno o alquilo, o R27 y R28 juntos son -(CH2 )n donde n es 2 o 3 y R29 es hidrógeno o alquilo; o -COR30 donde R30 es alquilo, heteroalquilo, heterociclialquilo, arilo, aralquilo, heteroarilo, o heteroaralquilo; en donde el alquilo tiene de 1 a 6 átomos de carbono, el alquenilo tiene de 2 a 6 átomos de carbono, el alquinilo tiene de 3 a 6 átomos de carbono, el cicloalquilo tiene de 3 a 6 átomos de carbono, el heteroalquilo tiene de 1 a 6 átomos de carbono, el heterociclilo tiene un anillo de 3 a 8 átomos de carbono en el cual uno o dos átomos del anillo son heteroátomos seleccionados de N; O o S(O)n (en donde n es un entero de 0 a 2), los restantes átomos del anillo son carbonos en donde uno o dos átomos de carbono pueden opcionalmente ser reemplazados por un grupo carbonilo; amino monosustituido significa un radical -NHR en donde R es alquilo, alquenilo, heteroalquilo, haloalquilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo o un grupo protector de amino y amino disubstituido significa un radical -NRR en el que R y R´ son independientemente alquilo, alquenilo, heteroalquilo, haloalquilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo; y sus sales profármacos, isómeros individuales y mezclas de isómeros farmacéuticamente aceptables, con la condición de que ambos R3 y R6 no son amino, amino monosubstituido o amino disubstituido.
CO98060325A 1997-10-20 1998-10-16 Piridinas biciclicas, intermediarios de ellas, proceso para su preparacion y preparaciones farmaceuticas que contienen las mismas. CO4980857A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6254897P 1997-10-20 1997-10-20
US7551598P 1998-02-20 1998-02-20
US9691698P 1998-08-18 1998-08-18

Publications (1)

Publication Number Publication Date
CO4980857A1 true CO4980857A1 (es) 2000-11-27

Family

ID=27370326

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98060325A CO4980857A1 (es) 1997-10-20 1998-10-16 Piridinas biciclicas, intermediarios de ellas, proceso para su preparacion y preparaciones farmaceuticas que contienen las mismas.

Country Status (26)

Country Link
US (4) US6316464B1 (es)
EP (1) EP1025102B1 (es)
JP (1) JP3579350B2 (es)
KR (1) KR100378937B1 (es)
CN (1) CN1279682A (es)
AT (1) ATE267200T1 (es)
AU (1) AU745579B2 (es)
BR (1) BR9812944A (es)
CA (1) CA2306870A1 (es)
CO (1) CO4980857A1 (es)
DE (1) DE69824029T2 (es)
ES (1) ES2221213T3 (es)
HR (1) HRP20000209A2 (es)
HU (1) HUP0100348A3 (es)
ID (1) ID27124A (es)
IL (1) IL135302A0 (es)
MA (1) MA26555A1 (es)
NO (1) NO316734B1 (es)
NZ (1) NZ503685A (es)
PE (1) PE120999A1 (es)
PL (1) PL340412A1 (es)
RU (1) RU2219178C2 (es)
TR (1) TR200001079T2 (es)
TW (1) TWI224596B (es)
WO (1) WO1999020624A1 (es)
YU (1) YU22000A (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT948495E (pt) * 1996-11-19 2004-08-31 Amgen Inc Agentes anti-inflamatorios de pirrolo fundido substituidos em arilo e heteroarilo
WO2000002561A1 (en) * 1998-07-13 2000-01-20 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
CA2320730A1 (en) * 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
BR0014973A (pt) * 1999-10-21 2002-07-16 Hoffmann La Roche Ag G Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
CZ20021744A3 (cs) * 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyklické dusíkové heterocykly substituované heteroalkylaminoskupinou jako inhibitory P38 proteinkinázy
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
IL150388A0 (en) * 1999-12-24 2002-12-01 Aventis Pharma Ltd Azaindoles
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US20090306182A1 (en) * 2002-02-20 2009-12-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MAP KINASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR100714519B1 (ko) * 2002-03-07 2007-05-07 에프. 호프만-라 로슈 아게 이환 피리딘 및 피리미딘 ｐ38 키나아제 억제제
IL164187A0 (en) 2002-03-28 2005-12-18 Eisai Co Ltd 7-Azaindole derivatives and pharmaceutical compositions containing the same
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
SG135051A1 (en) * 2002-06-20 2007-09-28 Aventis Pharma Ltd Azaindoles
MXPA05001332A (es) * 2002-08-06 2005-04-28 Hoffmann La Roche 6-alcoxi-pirido-pirimidinas como inhibidores de cinasa del map p-38.
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
WO2004053107A2 (en) * 2002-12-06 2004-06-24 Scios Inc. Methods for treating diabetes
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1606283B1 (en) * 2003-03-03 2008-10-08 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
US7687506B2 (en) * 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US7638530B2 (en) * 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
US7902192B2 (en) 2003-05-15 2011-03-08 Arqule, Inc. Inhibitors of P38 and methods of using the same
EP1628975A2 (en) * 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitors
US20060241150A1 (en) * 2003-06-06 2006-10-26 Weiner David B P38 kinase inhibitor compositions and methods of using the same
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
DE602004032579D1 (de) 2003-11-25 2011-06-16 Virginia Tech Intell Prop Zusammensetzung für den tierischen verzehr sowie verfahren zur reduktion der map-kinaseaktivität
EP1716150B1 (en) * 2004-01-22 2008-04-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
US20050203111A1 (en) * 2004-03-12 2005-09-15 Vvii Newco 2003, Inc. Compositions and methods for preventing and treating skin and hair conditions
EP1740047A2 (en) * 2004-03-11 2007-01-10 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
US20080113016A1 (en) * 2004-07-26 2008-05-15 Gary Steven Firestein Method for Prevention or Treatment of Inflammatory Disease
TW200615268A (en) * 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
EP1809636A1 (en) 2004-10-19 2007-07-25 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US20090131430A1 (en) * 2004-11-23 2009-05-21 Palle Venkata P Pyrido'2,3-dipyrimidines as anti-inflammatory agents
EP1846403A1 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
GB0516156D0 (en) * 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
MY151835A (en) * 2006-01-31 2014-07-14 Array Biopharma Inc Kinase inhibitors and methods of use thereof
JP2009528991A (ja) * 2006-02-14 2009-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なピロロ（３，２−ｃ）ピリジン
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
US7687893B2 (en) 2006-12-27 2010-03-30 Amkor Technology, Inc. Semiconductor package having leadframe with exposed anchor pads
WO2008114119A2 (en) * 2007-03-20 2008-09-25 Cadila Pharmaceuticals Limited P38 inhibitors
GB0708141D0 (en) 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
JP5767965B2 (ja) * 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
WO2010046215A2 (en) * 2008-10-21 2010-04-29 Syngenta Participations Ag Diaza-indole derivatives and their use as fungicides
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
MY179042A (en) 2008-12-05 2020-10-26 Abbvie Bahamas Ltd Kinase inhibitors with improved cyp safety profile
CN104130976A (zh) 2008-12-17 2014-11-05 斯克里普斯研究所 干细胞的产生和保持
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US20170117214A1 (en) 2009-01-05 2017-04-27 Amkor Technology, Inc. Semiconductor device with through-mold via
EP2245936A1 (en) 2009-04-27 2010-11-03 Bayer CropScience AG Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
EP2338890A1 (en) 2009-12-22 2011-06-29 Bayer CropScience AG 4,7-Diazaindole derivatives and their use as fungicides
US8450320B2 (en) * 2010-04-16 2013-05-28 Abbvie Inc. Pyrrolopyrazinone inhibitors of kinases
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
AU2012301617A1 (en) 2011-09-02 2014-04-17 Salk Institute For Biological Studies CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
EP2843049B1 (en) 2012-04-27 2018-04-11 Keio University Neuronal differentiation promoter
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
US20140303121A1 (en) * 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
PL2970265T3 (pl) * 2013-03-15 2018-11-30 Plexxikon Inc. Heterocykliczne związki i ich zastosowania
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CA2903275A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015023811A2 (en) 2013-08-16 2015-02-19 The J. David Gladstone Institutes Compositions and methods for identifying latently infected cells
JP6818676B2 (ja) 2014-05-16 2021-01-20 アトリバ セラピューティクス ゲーエムベーハー インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
US20180325947A1 (en) 2015-10-27 2018-11-15 Children's Hospital Medical Center Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
JP7289301B2 (ja) 2017-12-18 2023-06-09 ブリストル－マイヤーズ スクイブ カンパニー ４－アザインドール化合物
WO2022023339A1 (en) 2020-07-29 2022-02-03 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
WO2023280911A1 (en) 2021-07-06 2023-01-12 Westfälische Wilhelms-Universität Münster P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm
WO2023147015A1 (en) * 2022-01-27 2023-08-03 The Broad Institute, Inc. Substituted heterocyclic csnk1 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU371228A1 (ru) 1971-04-02 1973-02-22 Всесоюзный научно исследовательский химико фармацевтический институт Серго Орджоникидзе Способ получения пирроло-
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
JPS56104870A (en) 1980-01-25 1981-08-20 Dai Ichi Seiyaku Co Ltd 2-halogeno-3,4-dihydro-condensed pyrimidine and its preparation
US4767766A (en) * 1987-01-30 1988-08-30 Merck & Co., Inc. Derivatives of 3-hydroxyazabenzo(B)thiophene useful as 5-lipoxygenase inhibitors
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5236925A (en) 1991-10-24 1993-08-17 American Home Products Corporation Fused pyrimidines as angiotensin II antagonists
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
JPH10501532A (ja) 1994-06-09 1998-02-10 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0871444A4 (en) * 1995-08-10 1999-01-13 Merck & Co Inc 2.5 SUBSTITUTED ARYL PYRROL, THE COMPOSITIONS THAT CONTAIN AND THE USE THEREOF
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
PT948495E (pt) * 1996-11-19 2004-08-31 Amgen Inc Agentes anti-inflamatorios de pirrolo fundido substituidos em arilo e heteroarilo
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
KR100378937B1 (ko) 2003-05-09
HUP0100348A3 (en) 2002-12-28
US20010044538A1 (en) 2001-11-22
YU22000A (sh) 2003-01-31
WO1999020624A1 (en) 1999-04-29
EP1025102A1 (en) 2000-08-09
JP3579350B2 (ja) 2004-10-20
AU745579B2 (en) 2002-03-21
US20020013354A1 (en) 2002-01-31
CA2306870A1 (en) 1999-04-29
TR200001079T2 (tr) 2000-07-21
HUP0100348A2 (hu) 2001-08-28
JP2001520227A (ja) 2001-10-30
AU9749998A (en) 1999-05-10
ATE267200T1 (de) 2004-06-15
DE69824029D1 (de) 2004-06-24
KR20010031285A (ko) 2001-04-16
US20030139462A1 (en) 2003-07-24
IL135302A0 (en) 2001-05-20
US6479507B2 (en) 2002-11-12
NO20001940L (no) 2000-04-13
ID27124A (id) 2001-03-01
PL340412A1 (en) 2001-01-29
CN1279682A (zh) 2001-01-10
US6316464B1 (en) 2001-11-13
NO316734B1 (no) 2004-04-19
US6630485B2 (en) 2003-10-07
TWI224596B (en) 2004-12-01
NZ503685A (en) 2002-05-31
PE120999A1 (es) 1999-12-01
RU2219178C2 (ru) 2003-12-20
ES2221213T3 (es) 2004-12-16
DE69824029T2 (de) 2005-05-12
NO20001940D0 (no) 2000-04-13
MA26555A1 (fr) 2004-12-20
EP1025102B1 (en) 2004-05-19
HRP20000209A2 (en) 2001-04-30
BR9812944A (pt) 2000-08-08

Similar Documents

Publication Publication Date Title
CO4980857A1 (es) Piridinas biciclicas, intermediarios de ellas, proceso para su preparacion y preparaciones farmaceuticas que contienen las mismas.
ATE204269T1 (de) Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
AR018634A1 (es) Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR035548A1 (es) Compuestos organicos
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
ATE102193T1 (de) Thiazolidinedionederivate.
KR950010893A (ko) 자궁내막증 억제 방법
AR016817A1 (es) Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
UY25282A1 (es) Procedimientos para la preparacion de derivados de acido hidroxamico inhibidores de metaloproteasas de matriz (mmp).
FI954105A (fi) Uusia 4-aminopyridiinejä, niiden valmistusmenetelmä sekä näitä yhdisteitä sisältäviä lääkkeitä
KR890012967A (ko) 피페리딘 유도체
KR950010892A (ko) 자궁 섬유증 억제 방법
ATE165095T1 (de) Heterocyclische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ZA943381B (en) 19-nor steroids having a phenoxyalkylsulphonamide or phenoxyalkylsulphonylurea chain in position 11beta preparation process and intermediates use as medicaments and pharmaceutical compositions containing them
PT90740A (pt) Processo para a preparacao de oligopeptideos com aminoacidos analogos de prolina ciclicos, e de composicoes farmaceuticas que os contem
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
AR002741A1 (es) Benciloxicarbonilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico asi como medicamentoque las contiene
KR910000614A (ko) 신규 화합물
KR920016089A (ko) 제i형 당뇨병의 치료방법
ATE106868T1 (de) N-((2-oxopyrrolidin-1-yl)acetyl>piperazin- derivate und arzneimittel gegen senile dementia.
AR035375A1 (es) Compuesto derivado de pirrol sustituido, composicion farmaceutica y su uso en la fabricacion de un medicamento para inhibir la farnesiltransferasa
KR900001673A (ko) N-치환 아미드 유도체